

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D2Serial No.
09/648,896LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)Applicant
Cleland et al.Filing Date
25 Aug 2000Group
1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	248	4,714,759	22.12.87	Whitaker, Jr.			
	249	4,816,567	28.03.89	Cabilly et al.			
	250	4,861,579	29.08.89	Meyer et al.			
	251	4,946,788	07.08.90	Delespesse			
	252	4,962,035	09.10.90	Leder et al.			
	253	5,091,313	25.02.92	Chang, T.			
	254	5,231,026	27.07.93	Chang, T.			
	255	5,252,467	12.10.93	Chang, T.			
	256	5,254,671	19.10.93	Chang, T.			
	257	5,260,416	09.11.93	Chang, T.			
	258	5,274,075	28.12.93	Chang, T.			
	259	5,292,867	08.03.94	Chang, T.			
	260	5,342,924	30.08.94	Chang, T.			
	261	5,362,643	08.11.94	Chang, T.			
	262	5,420,251	30.05.95	Chang et al.			
	263	5,422,258	06.06.95	Chang, T.			
	264	5,428,133	11.12.91	Chang, T.			
	265	5,654,403	05.08.97	Smith et al.			
	266	5,792,838	11.08.98	Smith et al.			
	267	5,942,210	24.08.99	Ultee et al.			
	268	5,965,709	12.10.99	Presta et al.			
	269	6,080,429	27.06.00	Cleland et al.			
	270	6,165,464	26.12.00	Hudziak et al.			
	271	6,267,958	31.07.01	Andya et al.			

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
CY	272	171,496 ✓	19.02.86	EPO			
	273	173,494 ✓	05.03.86	EPO			
	274	184,187 ✓	11.06.86	EPO			
	275	255,249 ✓	03.02.88	EPO			
	276	263,655 ✓	13.04.88	EPO			
	277	317,295 ✓	24.05.89	EPO			
	278	589,840 ✓	30.03.94	EPO			
	279	617,127 ✓	28.09.94	EPO			
	280	648,499 ✓	19.04.95	EPO			

Examiner

Chris Yoh HX

Date Considered

8/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09/648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1642

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
CY	281	59-44399 ✓	12.03.84	JAPAN (TRANSLATION ATTACHED)				
	282	WO 86/01533 ✓	13.03.86	PCT				
	283	WO 89/04834 ✓	01.06.89	PCT				
	284	WO 89/06138 ✓	13.07.89	PCT				
	285	WO 91/11456 ✓	08.08.91	PCT				
	286	WO 93/04173 ✓	04.03.93	PCT				
	287	WO 93/19197 ✓	30.09.93	PCT				
	288	WO 95/15977 ✓	15.06.95	PCT				
	289	WO 97/04807 ✓	13.02.97	PCT				
	290	WO 97/10004 ✓	20.03.97	PCT				
	291	WO 97/33616 ✓	18.09.97	PCT				
	292	WO 99/01556 ✓	14.01.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CY	293	Cleland et al., "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:514-515 (1995) ✓
CY	294	Kern et al., "Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody" <u>American Journal of Respiratory Cell & Molecular Biology</u> 9(4):448-454 (Oct 1993) ✓
CY	295	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990) ✓
CY	296	Ohnishi et al., "Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody" <u>British Journal of Cancer</u> 71(5):969-973 (May 1995) ✓
CY	297	Ressing et al., "The influence of sucrose, dextran, and hydroxypropyl-1/42-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG _{2a} monoclonal antibody (MN12)" <u>Pharmaceutical Research</u> 9(2):266-270 (1992) ✓
CY	298	Tokuda et al., "In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product" <u>British Journal of Cancer</u> 73(11):1362-1365 (Jun 1996) ✓

Examiner

Christopher H. K.

Date Considered

8/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.